AbbVie posts updates on three early-stage trials: obesity, drug interaction, glabellar lines

AbbVie had three registry updates this week across early-phase programs.

• AbbVie's Phase 1b study of ABBV-295, "A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Subcutaneous Doses of ABBV-295 in Adult Subjects With Obesity" (NCT07291232), is listed as active not recruiting, with a start date of 2025-11-19 and estimated primary completion in 2027-04.¹ The study has an actual enrollment of 80 participants¹ and tracks percent change in body weight from baseline as one of its outcome measures.¹
• A completed Phase 1 study examined how itraconazole affects nacresertib pharmacokinetics, titled "A Phase 1 Open-Label, Two-Period Study to Evaluate the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of Nacresertib in Healthy Adult Subjects" (NCT07649954). The trial is listed as completed, with an actual start of 2026-06-23 and actual completion on 2026-10-05², and enrolled 12 participants in a crossover design.²
• AbbVie's Phase 1 study combining AGN-151586 with BOTOX for glabellar lines (NCT07756580) remains active not recruiting, with Cohort 1 participants receiving BOTOX on Day 14 and Cohort 2 on Day 21 following AGN-151586 on Day 1³. The study has an actual enrollment of 143 participants³ and an estimated primary completion in 2027-02, per the registry.